ESMO 2023 | BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer

Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK, discusses data from Arm 7 of the on-going Phase I/II BEGONIA (NCT03742102) trial, which is evaluating the efficacy and safety of durvalumab in combination with novel therapies in the treatment of first-line locally advanced or metastatic triple-negative breast cancer (a/mTNBC). Arm 7 aims to assess datopotamab deruxtecan (Dato-DXd) in combination with durvalumab. The data showed that the regimen exhibited manageable safety and highly promising efficacy. The trial reported an objective response rate (ORR) of 79%, a median progression-free survival (PFS) of 13.8 months, and median duration of response (DoR) of 15.5 months. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.